Literature DB >> 29285200

Activation of PGE2/EP2 and PGE2/EP4 signaling pathways positively regulate the level of PD-1 in infiltrating CD8+ T cells in patients with lung cancer.

Jinhong Wang1, Li Zhang2, Dong Kang3, Deguang Yang4, Ying Tang5.   

Abstract

The present study aimed to identify the level of programmed death-1 (PD-1) expression in infiltrating cluster of differentiation (CD)4+ and CD8+ T cells isolated from lung cancer tissues, and investigated whether the level of PD-1 expression may be directly regulated by lung cancer cells via prostaglandin E2 (PGE2)-associated signaling pathways in patients with lung cancer. A total of 75 patients with lung cancer were enrolled in the present study. The percentage of infiltrating CD4+ and CD8+ T cells was determined by flow cytometry. ELISA was performed to evaluate the concentration of PGE2 in lung cancer tissue homogenate. The correlation between PGE2 and PD-1 expression levels in CD8+ T cells was assessed by Spearman's rank correlation test. The expression levels of PD-1 and PGE2 receptors were determined by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. The level of PD-1 expression in infiltrating CD8+ T cells was gradually increased as the stage of lung cancer increased. The level of PD-1 expression was also positively associated with the concentration of PGE2 in lung cancer tissues. Furthermore, the level of PD-1 expression was closely associated with the PGE2/EP2 and PGE2/EP4 signaling pathways. The activation of PGE2-associated EP2- and EP4-pathways may positively regulate the level of PD-1 in infiltrating CD8+ T cells, which results in immune tolerance in the lung cancer microenvironment.

Entities:  

Keywords:  infiltrating T lymphocytes; lung cancer; programmed cell death-1; prostaglandin E2

Year:  2017        PMID: 29285200      PMCID: PMC5738690          DOI: 10.3892/ol.2017.7279

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

Authors:  G O'Callaghan; A Houston
Journal:  Br J Pharmacol       Date:  2015-10-26       Impact factor: 8.739

3.  Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.

Authors:  Laura von der Emde; Diane Goltz; Stefan Latz; Stefan C Müller; Glen Kristiansen; Jörg Ellinger; Isabella Syring
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

4.  Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells.

Authors:  Catalina Lee-Chang; Monica Bodogai; Alejandro Martin-Montalvo; Katarzyna Wejksza; Mitesh Sanghvi; Ruin Moaddel; Rafael de Cabo; Arya Biragyn
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

5.  Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse.

Authors:  C Nataraj; D W Thomas; S L Tilley; M T Nguyen; R Mannon; B H Koller; T M Coffman
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 6.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

7.  Effect of Lactobacillus salivarius on Th1/Th2 cytokines and the number of spleen CD4⁺ CD25⁺ Foxp3⁺ Treg in asthma Balb/c mouse.

Authors:  Xiang Yun; Yunxiao Shang; Miao Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 8.  New molecularly targeted therapies for lung cancer.

Authors:  Sophie Sun; Joan H Schiller; Monica Spinola; John D Minna
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

9.  Prostaglandin E2 stimulates normal bronchial epithelial cell growth through induction of c-Jun and PDK1, a kinase implicated in oncogenesis.

Authors:  Yu Fan; Ye Wang; Ke Wang
Journal:  Respir Res       Date:  2015-12-18

10.  Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth.

Authors:  Hideki Amano; Izumi Hayashi; Hirahito Endo; Hidero Kitasato; Shohei Yamashina; Takayuki Maruyama; Michiyoshi Kobayashi; Kazutoyo Satoh; Masami Narita; Yukihiko Sugimoto; Takahiko Murata; Hirokuni Yoshimura; Shuh Narumiya; Masataka Majima
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

View more
  17 in total

1.  Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.

Authors:  Yamato Sajiki; Satoru Konnai; Tomohiro Okagawa; Asami Nishimori; Naoya Maekawa; Shinya Goto; Kei Watari; Erina Minato; Atsushi Kobayashi; Junko Kohara; Shinji Yamada; Mika K Kaneko; Yukinari Kato; Hirofumi Takahashi; Nobuhiro Terasaki; Akira Takeda; Keiichi Yamamoto; Mikihiro Toda; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  J Immunol       Date:  2019-07-31       Impact factor: 5.422

Review 2.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

3.  Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma.

Authors:  Ruida Hou; Ying Yu; Madison N Sluter; Lexiao Li; Jiukuan Hao; Jie Fang; Jun Yang; Jianxiong Jiang
Journal:  Cell Rep       Date:  2022-06-21       Impact factor: 9.995

4.  The COX-2-PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas.

Authors:  Jie Wei; Jinyu Zhang; Dingzhi Wang; Bo Cen; Jessica D Lang; Raymond N DuBois
Journal:  Cancer Prev Res (Phila)       Date:  2022-05-03

5.  Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

Authors:  Federico Nichetti; Francesca Ligorio; Emma Zattarin; Diego Signorelli; Arsela Prelaj; Claudia Proto; Giulia Galli; Antonio Marra; Giulia Apollonio; Luca Porcu; Filippo de Braud; Giuseppe Lo Russo; Roberto Ferrara; Marina Chiara Garassino
Journal:  Cancers (Basel)       Date:  2019-12-25       Impact factor: 6.639

6.  Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.

Authors:  Justine E Roderick; Kayleigh M Gallagher; Leonard C Murphy; Kevin W O'Connor; Katherine Tang; Boyao Zhang; Michael A Brehm; Dale L Greiner; Jun Yu; Lihua Julie Zhu; Michael R Green; Michelle A Kelliher
Journal:  Blood       Date:  2021-01-28       Impact factor: 25.476

Review 7.  Blocking prostanoid receptors switches on multiple immune responses and cascades of inflammatory signaling against larval stages in snail fever.

Authors:  Sameh Saber; Suliman Y Alomar; Galal Yahya
Journal:  Environ Sci Pollut Res Int       Date:  2022-04-09       Impact factor: 5.190

8.  Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells.

Authors:  Laia Gorchs; Carlos Fernández Moro; Peter Bankhead; Katharina P Kern; Imrul Sadeak; Qingda Meng; Elena Rangelova; Helen Kaipe
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

9.  Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma.

Authors:  Alison L Halpern; Patrick D Kohtz; Jessica Y Rove; Lihua Ao; Xianzhong Meng; David A Fullerton; Michael J Weyant
Journal:  Mol Cell Biochem       Date:  2019-01-25       Impact factor: 3.396

Review 10.  Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer.

Authors:  Rei Mizuno; Kenji Kawada; Yoshiharu Sakai
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.